Atoltivimab, maftivimab, and odesivimab-ebgn

(Inmazeb®)

Atoltivimab, maftivimab, and odesivimab-ebgn

Drug updated on 5/17/2024

Dosage FormInjection (intravenous; atoltivimab/maftivimab/odesivimab: 241.7 mg/241.7 mg/241.7 mg per 14.5 mL [16.67 mg/16.67 mg/16.67 mg per mL] in a single dose vial; atoltivimab/maftivimab/odesivimab: 483.3 mg/483.3 mg/483.3 mg per 14.5 mL [33.33 mg/33.33 mg/33.33 mg per mL] in a single-dose vial)
Drug ClassZaire ebolavirus glycoprotein directed human monoclonal antibodies
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Atoltivimab, maftivimab, and odesivimab-ebgn (Inmazeb) is indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.
  • Two studies compared Inmazeb's safety and efficacy with other treatments such as ZMapp, Ebanga, REGN-EB3, mAb114, and remdesivir.
  • When administered at a dose of 3 ml/kg IV, Inmazeb reduced the mortality rate by 17% in subjects with Ebola Virus Disease (EVD), demonstrating higher efficacy than both ZMapp, which has an effectiveness of 91.2%, and Ebanga, which showed a mortality rate of 35.1% at a single IV dose.
  • The study provides insights into the efficacy of REGN-EB3 and mAb114; both significantly reduce mortality compared to standard care or other treatments like remdesivir or even Inmazeb itself.
  • The studies do not extensively detail subgroup considerations beyond broad indication for adult and pediatric patients, including neonates born to mothers who are RT-PCRT positive for Zaire ebolavirus infection.
  • The safety profile across different EVD treatments seems comparable, as fever, tachycardia, and symptoms associated with the disease and its treatment are common adverse effects observed across all therapies mentioned here.